Eli Lilly posted a blockbuster second quarter fueled by continued demand for its portfolio of GLP-1 medications, though one glaring question hung over the print. The world’s biggest drugmaker by market value reported adjusted earnings of $8.38 a share in the period, better than the $6.01 consensus estimate among analysts polled by FactSet. Revenue surged 48% to nearly $23 billion—Wall Street was looking for $20.7 billion.